Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
Cell Therapy News
Cell Therapy News is an online resource dedicated to sharing the latest cell therapy, gene therapy, and regenerative medicine research.
Gene Editing for Collagen Disorders: Current Advances and Future Perspectives
[Gene Therapy] Scientists provide an overview of current gene-editing strategies aimed at collagen-related diseases, including osteogenesis imperfecta, Alport syndrome, and dystrophic epidermolysis bullosa.
A Clonally Expanded Nodal T Cell Population Diagnosed As T Cell Lymphoma after CAR-T Therapy
[Nature Communications] Investigators described a patient with diffuse large B-cell lymphoma who developed new lymphadenopathy 2.5 years after CAR-T in the context of COVID-19 infection with histopathologic features consistent with T cell lymphoma.
Targeted Gene Editing and Near-Universal cDNA Insertion of CYBA and CYBB As a Treatment for Chronic Granulomatous Disease
[Nature Communications] Researchers developed CRISPR/Cas9-based gene editing strategies for correction of variants in the CYBA and CYBB genes causing chronic granulomatous disease.
Functional Avidity of Anti-B7H3 CAR-T Constructs Predicts Antigen Density Thresholds for Triggering Effector Function
[Nature Communications] Scientists evaluated the relationship between the antibody/antigen affinity of three clinical candidate binders and cellular avidity, duration of sustained cytotoxicity in tumoroid re-stimulation assays, and in vivo anti-tumoral responses.
Preclinical Development and a Phase I Trial of IMC001, an EpCAM-Targeted CAR-T Cell Therapy, in Patients with Advanced Gastric Cancer
[Molecular Therapy] The authors evaluated the specificity, efficacy, and safety of IMC001 in preclinical models and a Phase I dose-escalation/expansion trial in patients who had failed at least two lines of therapy.
A Novel Chimeric Antigen Receptor T-Cell Therapy Targeting CD84 for the Treatment of Acute Myeloid and T-Cell Lymphoblastic Leukemias
[Leukemia] Investigators introduced a first-in-class CART-cell therapy targeting CD84, a novel antigen, for the treatment of relapsed or refractory acute myeloid leukemia and T cell acute lymphoblastic leukemia. CD84 is highly expressed on leukemic blasts, with limited expression on hematopoietic stem progenitor cells (HSPC), and is largely absent in healthy human tissues.
ULBP2 CAR-T Cells Enhance Gastric Cancer Immunotherapy by Inhibiting CAF Activation
[Cell Death & Disease] Researchers identified UL16 binding protein 2 (ULBP2) as a potential therapeutic target in gstric cancer (GC). Mechanistically, ULBP2 overexpression activates the TGF-β signalling pathway, promoting the activation of cancer-associated fibroblasts (CAFs) and tumor progression in GC.
NKTR-255 Enhances Complete Response following CD19 CAR-T in Patients with Relapsed/Refractory Large B-Cell Lymphoma
[Blood Advances] In this Phase II, randomized, double-blind, placebo-controlled, multicenter study of NKTR-255 versus placebo following CD19 CAR T cell therapy, eligible patients with relapsed/refractory large B-cell lymphoma were treated with axicabtagene ciloleucel or lisocabtagene maraleucel.
Graduate Student Awarded Prestigious Fellowship to Improve CAR T-Cell Therapy for Cancer Patients
[University of Tennessee Health Science Center] Michaela Meehl has received a prestigious predoctoral fellowship from the National Cancer Institute to support her research on improving CAR-T cell therapy. The $131,712 award provides funds for three years of research.
Optimal Pairing of Binder and Costimulatory Domains Improves Dual CAR T Cell Efficacy
[Molecular Therapy] Researchers explored whether T cells expressing two CARs with distinct signaling motifs improve CAR T cell efficacy against leukemia and lymphoma.
Perineural Delivery of AAV2/9 in Non-Human Primate Is a Safe and Efficient Route for Gene Therapy in Charcot-Marie-Tooth Diseases
[Molecular Therapy-Methods & Clinical Development] The authors investigated the regional anesthesia standard perineural injection route in non-human primates using AAV2/9 expressing GFP and AAV2/9 expressing shRNA targeting human and monkey PMP22 mRNA.
Toward Improved AAV Gene Therapies for Retinal Disorders: Challenges and Advances
[Regenerative Medicine] Investigators highlight the current advances in retinal AAV design and delivery for treating retinal disorders.
Published since 2002, Cell Therapy News is our longest running online publication. Our editorial team curates the top publications, reviews, and news on in vivo gene therapy, cell therapy, and immunotherapy research. With over 15,000 subscribers and followers across our website, email newsletter, and Twitter feed, we are proud to facilitate the communication of cutting-edge cell therapy innovations.
